Affiliations 

  • 1 Amity Institute of Phytomedicine & Phytochemistry, Amity University Uttar Pradesh, Noida-201313, India
  • 2 Department of Pharmacy, Birla Institute of Technology & Science Pilani, Pilani Campus, Pilani-333031, Rajasthan, India
  • 3 School of Pharmacy, Maharaja Agrasen University, Atal Sikha Kunj, Kalujhanda, Baddi, Solan-174103, Himachal Pradesh, India
  • 4 Department of Chemistry, Faculty of Science, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia
Future Med Chem, 2021 02;13(3):269-286.
PMID: 33399497 DOI: 10.4155/fmc-2020-0257

Abstract

Reverse transcriptase and integrase are key enzymes that play a pivotal role in HIV-1 viral maturation and replication. Reverse transcriptase consists of two active sites: RNA-dependent DNA polymerase and RNase H. The catalytic domains of integrase and RNase H share striking similarity, comprising two aspartates and one glutamate residue, also known as the catalytic DDE triad, and a Mg2+ pair. The simultaneous inhibition of reverse transcriptase and integrase can be a rational drug discovery approach for combating the emerging drug resistance problem. In the present review, the dual inhibition of RNase H and integrase is systematically discussed, including rationality of design, journey of development, advancement and future perspective.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.